Case series:Chimeric Antigen Receptor T-Cell Immunotherapy

An open lable, single center, single arm clinical study for sequential infusion of anti-CD19 CAR-T and anti-CD22 CAR-T therapy following autologous hematopoietic stem cell transplantation (auto-HSCT) for relapsed, refractory and high-risk B cell lymphoma

A single center and open phase I clinical study on the safety and efficacy of ct103a cell infusion in the treatment of recurrent / refractory plasmacytoma

An open-label, single-center and single-arm clinical study of infusion of anti-CD19 or CD22 CAR-T cells (CT101A-19 or CT102A-22) for patients with relapsed/refractory/high risk B cell malignancies.

An open-label, single-center and single-arm clinical study for sequential infusion of anti-CD22 and anti-CD19 CAR-T cells for patients with relapsed or refractory B-cell malignancies

An open single center single arm clinical study for anti-BCMA CAR-T therapy for relapsed, refractory and high-risk BCMA+ tumor

Validity and security of leveraging CS1 chimeric antigen receptor T-cell therapy treating relapsed/ refractory/ high risk CS1+ hematological malignancy: a single-center, open, single-arm clinical study

An open-label, single-center and single-arm clinical study for infusion of anti-CD22 CAR-T cells for patients with relapsed or refractory B-cell malignancies

An open-label, single-center and single-arm clinical study for infusion of anti-CD20 CAR-T cells for patients with relapsed or refractory B-cell malignancies